Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Catalyst Health Ventures (CHV) is a venture capital firm based in Boston, Massachusetts, established to invest in transformative medical technology (MedTech) solutions that address global unmet healthcare needs. Founded by Darshana Zaveri and Joshua S. Phillips, CHV aims to support innovative healthcare solutions through close collaboration with entrepreneurs. The firm provides essential resources, mentorship, and connections to help navigate the complexities of the healthcare landscape.
Currently, CHV operates with a focus on early-stage investments, specifically targeting seed through Series B funding rounds. The firm has built a notable portfolio and has established a reputation for its commitment to high-value medical devices that can significantly impact healthcare. CHV's team comprises experienced professionals with backgrounds in healthcare and venture capital, enhancing its ability to support portfolio companies effectively.
CHV invests in early-stage companies developing breakthrough medical technologies, including therapeutic devices, digital health solutions, and diagnostic devices. The firm typically engages with companies at the seed through Series B stages, particularly during transitions from pre-clinical to clinical development. CHV seeks to support businesses that demonstrate capital efficiency, strong technological foundations, clear regulatory pathways, and scalable business models.
While the firm is agnostic to specific therapeutic areas, it shows a particular interest in high-value medical devices that can significantly impact healthcare. CHV's investment strategy emphasizes the importance of strong technological foundations and scalable business models, ensuring that the companies it backs are well-positioned for growth and success in the competitive MedTech sector.
CHV's portfolio includes several notable companies that have achieved significant milestones in the MedTech sector. The following companies are part of CHV's investment history:
These companies have been acquired by leading firms in the MedTech sector, showcasing CHV's ability to identify and support high-potential investments.
Darshana Zaveri - Founder & Managing Partner. Darshana has extensive experience in venture capital and healthcare, having previously worked at leading firms in the industry.
Joshua S. Phillips - Founder & Managing Partner. Joshua brings a wealth of knowledge in MedTech investments and has a strong track record of supporting early-stage companies.
David Mackey - Partner & Chief Financial Officer. David has a background in finance and operations, playing a crucial role in managing CHV's financial strategies.
Mimi Dunn - Senior Investment Analyst. Mimi focuses on evaluating potential investments and supporting portfolio companies with market analysis.
Joshua Lang, MD - Venture Advisor. Joshua provides medical expertise and insights to help guide CHV's investment decisions.
Neil Rens, MD, MBA, MSc - Venture Fellow. Neil contributes his medical and business acumen to support the firm's investment strategy.
To pitch to Catalyst Health Ventures, founders should use the investor portal available on their website. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. CHV prefers detailed information about the technology and its potential impact on healthcare.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial, as they can facilitate a more favorable review of the pitch.
In recent months, Catalyst Health Ventures has been active in promoting its portfolio and team developments. Notable blog posts include the commercial launch of Instylla's Embrace™ Hydrogel Embolic System, which represents a significant advancement in medical technology.
Additionally, CHV announced the promotion of David Mackey to Partner, reflecting the firm's commitment to internal growth and leadership development. Furthermore, a collaboration between Abbott and AtaCor Medical on advanced ICD technology was highlighted, showcasing CHV's engagement with industry advancements.
What are CHV's investment criteria?
CHV focuses on early-stage companies developing breakthrough medical technologies, particularly in therapeutic devices, digital health solutions, and diagnostics. The firm looks for businesses that demonstrate capital efficiency, strong technological foundations, clear regulatory pathways, and scalable business models.
How can I pitch to CHV?
Founders can pitch to CHV by visiting their website and submitting their information through the investor portal. It is recommended to include a detailed business plan and financial projections in the pitch deck.
What makes CHV different from other venture capital firms?
CHV differentiates itself through its deep focus on the MedTech sector and its commitment to providing hands-on support to portfolio companies. The firm collaborates closely with entrepreneurs, offering mentorship and resources tailored to the healthcare landscape.
What is the geographic focus of CHV?
CHV primarily invests in companies based in North America, allowing them to leverage their local expertise and network within the healthcare sector.
What is the typical check size for investments?
CHV typically invests in seed to Series B rounds, with check sizes varying based on the stage and needs of the company. Specific amounts are not disclosed, but the firm emphasizes supporting capital-efficient businesses.
What kind of post-investment involvement does CHV have?
CHV maintains active involvement with its portfolio companies, providing mentorship, operational support, and strategic guidance to help them navigate challenges and achieve growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.